Literature DB >> 27790301

The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis.

Ian Wright1, Andrea Civitarese1, Richard Baverstock2.   

Abstract

The use of intra-detrusor onabotulinumtoxinA (Botox®) in patients with myasthenia gravis has not been reported, and little evidence exists to substantiate a complete contraindication of Botox use in this population. Here, we present two cases of comorbid overactive bladder (OAB) and myasthenia gravis successfully treated with intra-detrusor Botox.

Entities:  

Year:  2016        PMID： 27790301      PMCID： PMC5065409          DOI： 10.5489/cuaj.3678

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  4 in total

1.  Systemic effect of local and small-dose botulinum toxin injection to unmask subclinical myasthenia gravis.

Authors:  Takeshi Iwase; Chie Iwase
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-21       Impact factor: 3.117

2.  Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis.

Authors:  M R Gonçalves; E R Barbosa; A A Zambon; P E Marchiori
Journal:  Arq Neuropsiquiatr       Date:  1999-09       Impact factor: 1.420

3.  Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia.

Authors:  A Fasano; A R Bentivoglio; T Ialongo; F Soleti; A Evoli
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

4.  Subclinical myasthenia gravis causing increased sensitivity to botulinum toxin therapy.

Authors:  Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2010-10-16       Impact factor: 3.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.